Design and preclinical characterization of ALXN1210: A novel anti-C5 antibody with extended duration of action

Eculizumab, a monoclonal antibody (mAb) directed against complement protein C5, is considered to be the current standard of care for patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome. This study describes the generation and preclinical attributes of ALXN1...

Descripción completa

Detalles Bibliográficos
Autores principales: Sheridan, Douglas, Yu, Zhao-Xue, Zhang, Yuchun, Patel, Rekha, Sun, Fang, Lasaro, Melissa A., Bouchard, Keith, Andrien, Bruce, Marozsan, Andre, Wang, Yi, Tamburini, Paul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5897016/
https://www.ncbi.nlm.nih.gov/pubmed/29649283
http://dx.doi.org/10.1371/journal.pone.0195909

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5897016/
https://www.ncbi.nlm.nih.gov/pubmed/29649283
http://dx.doi.org/10.1371/journal.pone.0195909

Ejemplares similares